Company: SHPH
Filing Date: 2025-01-15
Form Type: S-1
Source: 0001493152-25-002253
Chunk: 186

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-01-15
Form: S-1
Chunk 186
---
 RSUs granted typically vest annually in one third increments from the date of appointment.

During the three and nine months ended September 30, 2024 and 2023, pursuant to agreements with officers and consultants, 0and 53,455, respectively and 12,500and 19,916RSUs, respectively with a value of $ 0and $ 141,840, respectively, and $ 196,000and $ 291,400, respectively, were granted and compensation expense for RSUs of $ 45,275and $ 227,886, and $ 37,583and $ 95,438respectively, was incurred. During the three and nine months ended September 30, 2024 and 2023, $ 13,033and $ 60,019, respectively, and $ 0and $ 41,190, respectively was included in compensation under Research and Development.

| F-16 |

As of September 30, 2024, there was $ 145,504of unrecognized RSU compensation cost related to non-vested stock-based compensation arrangements which is expected to be recognized over a weighted-average period of 2.14years.

A summary of activity regarding the Restricted Stock Units issued follows:

Schedule of Restricted Stock Units (RSUs)

|                                 |     | Number of RSU |         |   |     | Weighted Average Fair Value Per RSU |       |
|:--------------------------------|:----|:--------------|--------:|:--|:----|:------------------------------------|------:|
| Outstanding, December 31, 2023  |     |               |  24,731 |   |     | $                                   | 11.76 |
| Granted                         |     |               |  53,455 |   |     |                                     |  2.65 |
| Forfeiture                      |     |               | (12,500 | ) |     |                                     |     - |
| Vested                          |     |               | (24,348 | ) |     |                                     |  9.06 |
| Outstanding, September 30, 2024 |     |               |  41,338 |   |     | $                                   |  5.14 |

Rights Offering and Financing Commitment

On February 7, 2024, the Company and its wholly-owned subsidiary, Shuttle Diagnostics, Inc., entered into a securities purchase agreement (the “Purchase Agreement”) with SRO, LLC,